Evidence map›Paper›PMID 38992700›Full record

ArticleActa neuropathologica communications2024

Early biomarkers in the presymptomatic phase of cognitive impairment: changes in the endocannabinoidome and serotonergic pathways in Alzheimer's-prone mice after mTBI.

Francesca Guida, Monica Iannotta, Anna Lauritano, Rosmara Infantino, Emanuela Salviati, Roberta Verde, Livio Luongo, Eduardo Maria Sommella, Fabio Arturo Iannotti, Pietro Campiglia and 3 more

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesca GuidaPharmacology Division, Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
Monica IannottaPharmacology Division, Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
Anna LauritanoEndocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Pozzuoli, (NA), Italy.
Rosmara InfantinoPharmacology Division, Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
Emanuela SalviatiDipartimento di Farmacia, Università Degli Studi di Salerno, Fisciano, (SA), Italy.
Roberta VerdeEndocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Pozzuoli, (NA), Italy.
Livio LuongoPharmacology Division, Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
Eduardo Maria SommellaDipartimento di Farmacia, Università Degli Studi di Salerno, Fisciano, (SA), Italy.
Fabio Arturo IannottiEndocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Pozzuoli, (NA), Italy.
Pietro CampigliaDipartimento di Farmacia, Università Degli Studi di Salerno, Fisciano, (SA), Italy.
Sabatino MaionePharmacology Division, Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
Vincenzo Di Marzo *Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Pozzuoli, (NA), Italy. vincenzo.dimarzo@criucpq.ulaval.ca.
Fabiana Piscitelli *Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Pozzuoli, (NA), Italy. fpiscitelli@icb.cnr.it.ORCID 0000-0001-9343-4622

Funding

Peer Reviewed Alzheimer's Research Program W81XWH1810000
6 · The paper itself

Abstract

backgroundDespite extensive studies on the neurobiological correlates of traumatic brain injury (TBI), little is known about its molecular determinants on long-term consequences, such as dementia and Alzheimer's disease (AD).

methodsHere, we carried out behavioural studies and an extensive biomolecular analysis, including inflammatory cytokines, gene expression and the combination of LC-HRMS and MALDI-MS Imaging to elucidate the targeted metabolomics and lipidomics spatiotemporal alterations of brains from wild-type and APP-SWE mice, a genetic model of AD, at the presymptomatic stage, subjected to mild TBI.

resultsWe found that brain injury does not affect cognitive performance in APP-SWE mice. However, we detected an increase of key hallmarks of AD, including Aβ

conclusionsMild TBI induces biochemical changes in AD genetically predisposed mice and the eCBome may play a role in the pathogenetic link between brain injury and neurodegenerative disorders also by interacting with the serotonergic system.

Indexed as

Alzheimer DiseaseCognitive DysfunctionEndocannabinoidsMice, TransgenicAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBiomarkersBrainBrain ConcussionDisease Models, AnimalMaleMiceMice, Inbred C57BLProdromal SymptomsSerotoninAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBiomarkersEndocannabinoidsSerotoninAlzheimer’s diseaseAPP-SWE miceDementiaEndocannabinoidomeSerotoninTraumatic brain injury

Identifiers

PMID38992700
PMCPMC11241935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.